Fuxu Wang
Impact in
- Clinical Biochemistry top 10%
- Advanced Glycation End Products research
Papers in
-
- Cell death mechanisms and regulation 4
- PI3K/AKT/mTOR signaling in cancer 3
- Hematology 15
- Multiple Myeloma Research and Treatments 6
- Hematopoietic Stem Cell Transplantation 5
- Co-authors
- Huijun Duan (3 shared papers)Hang Li (2 shared papers)Yanping Cao (2 shared papers)Qingjuan Liu (2 shared papers)Zelin Liu (2 shared papers)Xuejun Zhang (14 shared papers)Yunzhuo Ren (1 shared paper)Wei Liu (1 shared paper)
In The Last Decade
Fuxu Wang
45 papers receiving 456 citations
Peers
Comparison fields: 5 of 78
- Hematology 67
- Clinical Biochemistry 37
- Genetics 46
- Molecular Biology 264
- Immunology 77
Countries citing papers authored by Fuxu Wang
This map shows the geographic impact of Fuxu Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fuxu Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fuxu Wang more than expected).
Fields of papers citing papers by Fuxu Wang
This network shows the impact of papers produced by Fuxu Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fuxu Wang. The network helps show where Fuxu Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Fuxu Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 47 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 63 | |
| 2 | 2011 | 58 | |
| 3 | 2011 | 55 | |
| 4 | Mutation analysis of SHIP gene in acute leukemia. | 2004 | 40 |
| 5 | 2021 | 38 | |
| 6 | 2014 | 35 | |
| 7 | 2019 | 21 | |
| 8 | 2022 | 21 | |
| 9 | 2022 | 13 | |
| 10 | 2007 | 12 | |
| 11 | 2018 | 10 | |
| 12 | 2017 | 9 | |
| 13 | 2012 | 7 | |
| 14 | 2025 | 7 | |
| 15 | 2018 | 6 | |
| 16 | [Mutation analysis of SHIP gene in acute leukemia]. | 2004 | 5 |
| 17 | [In vitro effects of mevastatin on the proliferation and apoptosis in human multiple myeloma cell line U266]. | 2004 | 5 |
| 18 | 2025 | 4 | |
| 19 | 2021 | 4 | |
| 20 | [Apoptosis of the adriamycin-resistant leukemia cell line induced by the recombinant mutant human TNF-related apoptosis-inducing ligand combined with arsenic trioxide]. | 2008 | 4 |
About Fuxu Wang
Fuxu Wang is a scholar working on Molecular Biology, Hematology, Immunology, Oncology and Genetics, having authored 47 papers that have together received 463 indexed citations. Recurring topics across this work include Immune Cell Function and Interaction (6 papers), Multiple Myeloma Research and Treatments (6 papers), Hematopoietic Stem Cell Transplantation (5 papers), Cell death mechanisms and regulation (4 papers), CAR-T cell therapy research (4 papers), Lymphoma Diagnosis and Treatment (3 papers), PI3K/AKT/mTOR signaling in cancer (3 papers) and Advanced Glycation End Products research (3 papers). The work is most often cited by research in Hematology (67 citations), Clinical Biochemistry (37 citations), Genetics (46 citations), Molecular Biology (264 citations) and Immunology (77 citations). Fuxu Wang has collaborated with scholars based in China and Japan. Frequent co-authors include Huijun Duan, Hang Li, Yanping Cao, Qingjuan Liu, Zelin Liu, Xuejun Zhang, Yunzhuo Ren, Wei Liu, Yonghong Shi and Ryuzo Ohno. Their work appears in journals such as Blood, Journal of Inflammation Research, Stem Cell Research & Therapy, Cardiovascular Diabetology and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.